CTRO-1029

CTRO-1029 is a preclinical liver-targeted oligonucleotide therapeutic being developed by insitro for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD), specifically targeting liver fat and fibrosis. The drug is designed to modulate the expression or activity of insulin receptor substrate 1 (IRS1), a key protein involved in insulin signaling and metabolic regulation. Developed using insitro's machine learning-driven discovery platform, CTRO-1029 is part of a strategic collaboration with Eli Lilly, which serves as the modality partner for liver-targeted delivery. insitro retains full global rights to the program.